Novartis Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM - 8:00 PM ET, excluding holidays.
LUTATHERA results
Whether you've just been diagnosed or progressing while on SSAs, LUTATHERA can help slow down neuroendocrine tumor (NET) progression
If you're looking for a first treatment after diagnosis, LUTATHERA can help slow NET progression
In a study of 226 patients with faster-growing NETs, LUTATHERA with a somatostatin analogue (SSA) was shown to reduce how fast tumors grew or spread for over a year longer than SSA treatment alone.
Half of the patients taking LUTATHERA with an SSA did not have their cancer grow or spread for 22.8 months compared with 8.5 months with an SSA alone, roughly 3x more time without their cancer getting worse.
- ~14 months longer time to progression with LUTATHERA + SSA
With LUTATHERA, 4x more patients also saw their tumors shrink or disappear
More patients with faster-growing NETs saw their tumors shrink or disappear, also known as overall response, with LUTATHERA + SSA compared to SSA alone.
- This response lasted for ~2 years
The overall response rate (ORR) is the percentage of patients whose cancer got smaller or disappeared.
The data are from the NETTER-2 trial, which included 226 patients who were recently diagnosed with SSTR+ GEP-NETs that were faster growing (Ki-67, 10%–55%). They were split into 2 groups: 151 received LUTATHERA and a long-acting SSA, and 75 received a long-acting, high-dose SSA alone.
If your NETs have progressed on an SSA, LUTATHERA can delay NET progression for longer.
In a study of 229 patients whose NETs progressed on an SSA alone, LUTATHERA + SSA helped delay tumors from growing or spreading by more than 2 years.
LUTATHERA + SSA provided more time without their cancer growing or spreading: 28.4 months compared with 8.5 months with SSA alone, or more than 2 years without their cancer getting worse.
3x more patients who had SSA treatment before saw their tumor shrink or disappear with LUTATHERA
More patients whose NETs had progressed on an SSA alone saw their tumors shrink or disappear, also known as overall response, with LUTATHERA + SSA compared to those taking an SSA alone.
The data are from the NETTER-1 trial, which included 229 patients with SSTR+ NETs who had tumors that were slower growing (Ki-67, 0%–20%) and progressed on treatment with an SSA. They were split into 2 groups: 116 received LUTATHERA and a long-acting SSA, and 113 received a long-acting, high-dose SSA alone.
Hear from Donna, a real person treated with LUTATHERA
Since her diagnosis, Donna and her husband Don’s lives have been changed by NETs. Listen as they tell their story of self-advocacy and strength rooted in the love of their family. Join in Donna’s strength and watch her journey as one of the 20,000+ patients treated with LUTATHERA.